News - Genito-urinary

Filter

Current filters:

Genito-urinary

Popular Filters

10 to 34 of 36 results

Positive data expected for RedHill Biopharma's Crohn's disease candidate

22-04-2013

Analysts at Roth Capital Partners have launched coverage of Israel-based specialty pharma company RedHill…

FinancialGenito-urinaryPharmaceuticalRBH-104RedHill BiopharmaResearch

Lilly's ED drug Cialis meets endpoint in LUTS/BPH study

19-03-2013

US drug major Eli Lilly (NYSE: LLY) presented results yester day at the annual European Association of…

CialisEli LillyGenito-urinaryMen's HealthPharmaceuticalResearch

Dainippon Sumitomo partners with Nippon Shinyaku for urology drug AMP-986

12-03-2013

Japanese drugmakers Dainippon Sumitomo Pharma (TYO: 4506) and Nippon Shinyaku (TYO: 4516) have concluded…

AMP-986Asia-PacificDainippon Sumitomo PharmaGenito-urinaryLicensingNippon ShinyakuPharmaceutical

Research results for Pfizer's Chantix, Pristiq and Toviaz

27-01-2013

Global drugs behemoth Pfizer (NYSE: PFE) last week released a batch of new clinical trial data relating…

ChantixGenito-urinaryNeurologicalPfizerPharmaceuticalPristiqResearchToviaz

FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine

21-01-2013

US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

Astellas' Betmiga Oked in EU for overactive bladder

14-01-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has received approval from…

Astellas PharmaBetmigaEuropeGenito-urinarymirabegronPharmaceuticalRegulation

Watson gets FDA approval for generic Sanctura XR and Avapro

14-10-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has received approval from the US Food and Drug…

AllerganAvaproCardio-vascularGenericsGenito-urinaryNorth AmericaRegulationSanctura XRSanofiWatson Pharmaceuticals

Astellas links with KEK on tropical diseases; Upgraded by CS analysts

25-09-2012

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with the High Energy…

Astellas PharmaFinancialGenito-urinaryMyrbetriqOncologyPharmaceuticalResearchTropical diseasesXtandi

PDUFA Action Date for Astellas enzalutamide; Urogenix facility to close

07-08-2012

The US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date…

Astellas PharmaenzalutamideGenito-urinaryMedivationOncologyPharmaceuticalRegulationResearchUrogenixVaccines

Positive Ph IV data for Pfizer and UCB's Toviaz

06-08-2012

Global drugs behemoth Pfizer (NYSE: PFE) has released positive Phase IV study results assessing the efficacy…

Genito-urinaryPfizerPharmaceuticalResearchToviazUCB

FDA approves Astellas' Myrbetriq for overactive bladder

02-07-2012

The US Food and Drug Administration has approved Japanese drug major Astellas Pharma's (TYO: 4503) Myrbetriq…

Astellas PharmaGenito-urinarymirabegronMyrbetriqNorth AmericaPharmaceuticalRegulation

Kyowa Hakko debuts Poteligeo in Japan; co-promotes Minirinmelt with Ferring

29-05-2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has launched Poteligeo (mogamulizumab)…

Asia-PacificFerring PharmaceuticalsGenito-urinaryKyowa Hakko KirinMarkets & MarketingMinirinmeltOncologyPharmaceuticalPoteligeo

AstraZeneca to acquire Ardea Bio for $1.26 billion

23-04-2012

In line with its stated policy of making strategic, rather than mega, acquisitions, Anglo-Swedish drug…

Anti-Arthritics/RheumaticsArdea BiosciencesAstraZenecaBiotechnologyGenito-urinarylesinuradMergers & AcquisitionsPharmaceutical

Pharma giants set to lose dominance in urological disorders market

12-04-2012

Major pharmaceutical companies are predicted to lose their footing in the urological disorders market…

Genito-urinaryMarkets & MarketingPatentsPharmaceutical

Menarini extends febuxostat accord to more regions

12-04-2012

Japanese drugmaker Teijin Pharma and privately-owned Italian pharmaceutical company Menarini have signed…

febuxostatGenito-urinaryLicensingMenariniPharmaceuticalTeijin

FDA advisory panel backs Astellas OAB drug mirabegron

10-04-2012

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) said last week that the Reproductive…

Genito-urinarymirabegronNorth AmericaPharmaceuticalRegulation

Watson confirms Lumigan and Latisse patent challenges; favorable Sanctura ruling

05-04-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

AllerganGenericsGenito-urinaryLatisseLegalLumiganOphthalmicsPatentsSanctura XRWatson Pharmaceuticals

Botox shows efficacy in idiopathic overactive bladder, says Allergan

29-03-2012

USA-based Allergan (NYSE: AGN) announced that two Phase III clinical trials of Botox (onabotulinumtoxinA),…

AllerganBotoxGenito-urinaryPharmaceuticalRegulationResearch

10 to 34 of 36 results

Back to top